FIELD: biotechnology.
SUBSTANCE: present invention refers to immunology and biotechnology. Disclosed are novel embodiments of antibodies or antigen-binding fragments thereof, which specifically bind to MMP9 and contain variable regions of heavy and light chains, each of which is characterized by the presence of at least corresponding CDRs1-3. Described are: a coding antibody or its antigen-binding nucleic acid fragment, a recombinant expression vector thereof, a host cell carrying such a vector, and a method for producing an antibody using such a cell. Disclosed are an antibody-based pharmaceutical composition, as well as use of an antibody for preventing and/or treating MMP9-associated diseases. Also disclosed is a method for detecting the presence and/or concentration of the MMP9 protein ex vivo in a biological antibody-based sample, wherein the signal intensity correlates with the MMP-9 protein concentration in the sample.
EFFECT: use of the invention provides antibodies which are capable of neutralizing MMP9 activity, which can find application in preventing and/or treating inflammatory, autoimmune diseases and/or cancers associated with MMP9.
26 cl, 16 dwg, 8 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| ANTIBODIES TARGETING BONE | 2018 |
|
RU2801206C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
